Luminex (LMNX) 10-Q 1 Aug 19 2019 Q2 Quarterly report Financial data

COVER PAGE Document

COVER PAGE Document - shares	6 Months Ended
	Jun. 30, 2019	Jul. 31, 2019
COVER PAGE [Abstract]
Entity Central Index Key	0001033905
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	LMNX
City Area Code	(512)
Entity Address, Address Line One	12212 Technology Blvd.,
Entity Incorporation, State or Country Code	DE
Entity File Number	000-30109
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2019
Document Transition Report	false
Entity Registrant Name	LUMINEX CORPORATION
Entity Tax Identification Number	74-2747608
Entity Address, City or Town	Austin,
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78727
Local Phone Number	219-8020
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		45,047,039
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false

BALANCE SHEETS

BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 63,325	$ 76,441
Accounts Receivable, Net, Current	59,293	53,396
Inventory, Net	69,520	63,250
Other	10,130	9,657
Total current assets	202,268	202,744
Property, Plant and Equipment, Net	66,583	66,288
Intangible Assets, Net (Excluding Goodwill)	96,039	105,148
Goodwill	118,293	118,127
Operating Lease, Right-of-Use Asset	22,886	0
Deferred Income Tax Assets, Net	28,930	21,470
Other Assets, Noncurrent	9,700	11,398
Total assets	544,699	525,175
Current liabilities:
Accounts payable	19,017	14,504
Accrued Liabilities, Current	26,159	26,772
Short-term unearned revenue	8,974	10,099
Total current liabilities	54,150	51,375
Long-term unearned revenue	2,956	1,079
Operating Lease, Liability, Noncurrent	19,759	0
Other long-term liabilities	1,840	5,065
Total liabilities	78,705	57,519
Stockholders' Equity Attributable to Parent [Abstract]
Common Stock, Value, Outstanding	44	44
Preferred Stock, Value, Outstanding	0	0
Additional Paid in Capital	371,158	365,349
Accumulated Other Comprehensive Income (Loss), Net of Tax	(1,169)	(1,127)
Retained earnings	95,961	103,390
Stockholders' Equity Attributable to Parent	465,994	467,656
Liabilities and Equity	$ 544,699	$ 525,175

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	44,213,358	43,899,210
Common Stock, Shares, Outstanding	44,213,358	43,899,210
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

INCOME STATEMENTS

INCOME STATEMENTS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenues	$ 83,056	$ 79,578	$ 165,464	$ 162,240
Cost of Goods and Services Sold	37,829	30,272	74,430	59,346
Gross margin	45,227	49,306	91,034	102,894
Research and development	14,985	11,672	30,033	21,998
Selling, General and Administrative Expense	33,146	27,610	64,637	53,440
Amortization of Intangible Assets	2,852	2,166	5,704	4,332
Operating Expenses	50,983	41,448	100,374	79,770
Operating income	(5,756)	7,858	(9,340)	23,124
Other income, net	(158)	8	(98)	457
Income (Loss) Attributable to Parent, before Tax	(5,914)	7,866	(9,438)	23,581
Provision for income taxes	983	(2,197)	7,467	(4,515)
Net Income (Loss) Attributable to Parent	(4,931)	5,669	(1,971)	19,066
Net Income (Loss) Available to Common Stockholders, Basic	(4,896)	5,571	(1,973)	18,741
Net Income (Loss) Available to Common Stockholders, Diluted	$ (4,897)	$ 5,571	$ (1,974)	$ 18,742
Earnings Per Share [Abstract]
Earnings Per Share, Basic	$ (0.11)	$ 0.13	$ (0.04)	$ 0.43
Earnings Per Share, Diluted	$ (0.11)	$ 0.13	$ (0.04)	$ 0.43
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted Average Number of Shares Outstanding, Basic	44,157	43,734	44,054	43,599
Weighted Average Number of Shares Outstanding, Diluted	44,157	44,246	44,054	43,871
Common Stock, Dividends, Per Share, Declared	$ 0.06	$ 0.06	$ 0.12	$ 0.12
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	$ 91	$ (711)	$ (42)	$ (319)
Other Comprehensive Income (Loss), Net of Tax	91	(711)	(42)	(319)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ (4,840)	$ 4,958	$ (2,013)	$ 18,747

INCOME STATEMENTS INCOME STATEM

INCOME STATEMENTS INCOME STATEMENTS (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Operating Expenses	$ 50,983	$ 41,448	$ 100,374	$ 79,770
Operating Income (Loss)	$ (5,756)	$ 7,858	$ (9,340)	$ 23,124

CASH FLOWS STATEMENTS

CASH FLOWS STATEMENTS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net Income (Loss) Attributable to Parent	$ (4,931)	$ 5,669	$ (1,971)	$ 19,066
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation, Depletion and Amortization	7,104	6,130	13,993	12,023
Stock-based compensation expense	3,630	3,547	6,079	4,808
Increase (Decrease) in Deferred Income Taxes	(567)	2,308	(8,654)	3,761
Gain (Loss) on Disposition of Property Plant Equipment	78	111	172	111
Other Operating Activities, Cash Flow Statement	221	(1,158)	(21)	(1,127)
Changes in operating assets and liabilities:
Accounts receivable	1,446	(503)	(5,896)	5,053
Inventories	(5,498)	133	(5,985)	(2,602)
Operating Assets	1,133	(353)	3,403	(556)
Operating Liabilities	2,844	3,366	(7,556)	(8,073)
Accounts payable	52	(1,981)	4,169	(1,661)
Unearned revenue	370	231	1,050	653
Net cash from operations	5,882	17,500	(1,217)	31,456
Net Cash Provided by (Used in) Financing Activities [Abstract]
Common stock issued	983	2,290	1,786	3,416
Payments Related to Tax Withholding for Share-based Compensation	(13)	(13)	(2,085)	(2,016)
Common stock cash dividends paid	(2,699)	(2,678)	(5,395)	(5,302)
Net cash used in financing	(1,729)	(401)	(5,694)	(3,902)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Additions to property and equipment	(4,299)	(4,968)	(8,122)	(9,036)
Payments for (Proceeds from) Previous Acquisition	1,915	0	1,915	0
Payments to Acquire Notes Receivable	0	(500)	0	(1,000)
Payments to Acquire Equity Method Investments	0	(1,782)	0	(1,782)
Payments to Acquire Intangible Assets	0	0	0	(4,000)
Net cash used in investing	(2,384)	(7,250)	(6,207)	(15,818)
Effect of foreign exchange rates on cash and cash equivalents	(133)	492	2	148
Net change in cash and cash equivalents	1,636	10,341	(13,116)	11,884
Cash and cash equivalents, end of period	$ 63,325	$ 138,996	$ 63,325	$ 138,996

STOCKHOLDERS' EQUITY STATEMENTS

STOCKHOLDERS' EQUITY STATEMENTS - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated other comprehensive Income (loss)	Retained earnings
Stockholders' Equity Attributable to Parent	$ 467,656	$ 44	$ 365,349	$ (1,127)	$ 103,390
Common Stock, Shares, Outstanding	43,899,210
Stock Issued During Period, Value, Stock Options Exercised	$ 298	$ 0	298	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		204,216
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(2,072)	$ 0	(2,072)	0	0
Stock-based compensation expense	2,449	0	2,449	0	0
Net Income (Loss) Attributable to Parent	2,960	$ 0	0	0	2,960
Common stock cash dividends	(2,701)		25		(2,726)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		16,707
Net Income (Loss) Attributable to Parent	(1,971)
Stockholders' Equity Attributable to Parent	468,457	$ 44	366,049	(1,260)	103,624
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (133)	0	0	(133)	0
Common Stock, Shares, Outstanding	44,120,133
Stock Issued During Period, Value, Stock Options Exercised	$ 499	$ 0	499	0	0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures		11,033
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	(13)	$ 0	(13)	0	0
Stock-based compensation expense	3,630	$ 0	3,630	0	0
Stock Issued During Period, Shares, Employee Stock Purchase Plans		53,865
Stock Issued During Period, Value, Employee Stock Ownership Plan	966	$ 0	966	0	0
Net Income (Loss) Attributable to Parent	(4,931)	$ 0	0	0	(4,931)
Common stock cash dividends	(2,705)		27		(2,732)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		28,327
Stockholders' Equity Attributable to Parent	465,994	$ 44	371,158	(1,169)	95,961
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ 91	$ 0	$ 0	$ 91	$ 0
Common Stock, Shares, Outstanding	44,213,358

BUSINESS COMBINATIONS

BUSINESS COMBINATIONS	6 Months Ended
	Jun. 30, 2019
Business Combinations [Abstract]
BUSINESS COMBINATIONS	NOTE 2 — BUSINESS COMBINATIONS On December 31, 2018 , the Company completed its acquisition (the Acquisition) of EMD Millipore Corporation’s flow cytometry portfolio for $75 million , consisting of approximately $69.9 million paid under a Share and Asset Purchase Agreement (the Purchase Agreement) and approximately $5.1 million in committed inventory purchases, both of which are subject to adjustment. A purchase price reconciliation was completed in the quarter ended March 31, 2019 resulting in a decrease of the purchase price by $1.9 million . This adjustment resulted in a revised amount of $68.0 million paid under the Purchase Agreement. We expect to complete the committed inventory purchases in the third quarter of 2019. The Company financed the Acquisition with cash on hand. Luminex acquired 100% of the shares and equity of Amnis Corporation, a Washington corporation (Amnis), a wholly owned subsidiary of EMD Millipore Corporation, a Massachusetts corporation (itself an affiliate of Merck KgaA), and certain other assets owned by other affiliates of Merck KgaA (MilliporeSigma). The Acquisition expands Luminex’s existing offering of flow-based detection systems, which is centered around its innovative xMAP ® multiplexing technology, with more than 16,400 xMAP systems sold worldwide (some of which may be retired or otherwise not in use). MilliporeSigma’s flow cytometry portfolio included Amnis ® , a family of imaging flow cytometry products for cell-based analysis, as well as their Guava ® and Muse ® portfolio of products, which are economical systems based on microcapillary technologies. The purchase price was in excess of the fair value of the net assets acquired and, as a result, the Company recorded goodwill. A portion of the goodwill is deductible for tax purposes. The Company recorded approximately $2.7 million of acquisition-related costs during fiscal 2018. The impact of the Acquisition on our liquidity, and the Company’s committed inventory purchases is more fully described under “Liquidity and Capital Resources.” The following table summarizes the preliminary estimated fair values of assets acquired and liabilities assumed in connection with the Acquisition at December 31, 2018 and adjusted as of June 30, 2019 (in thousands): Net tangible assets assumed as of December 31, 2018 $ 8,725 Intangible assets subject to amortization 30,094 Deferred tax liabilities (3,653 ) Goodwill 32,812 Total purchase price $ 67,978 The Company is in the process of finalizing the calculations of the deferred tax assets and liabilities related to the Acquisition; thus the provisional measurement of deferred tax assets and liabilities and goodwill are subject to change. Information that existed prior to December 31, 2018 has become available that indicates adjustments are required to the purchase price allocation. Such adjustments have been included in the purchase price allocations retrospectively through revisions to the net tangible assets assumed, fair values of the intangible assets, deferred tax assets and liabilities and resulting goodwill recorded.

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4 — INVENTORIES, NET Inventories are stated at the lower of cost or net realizable value, with cost determined according to the standard cost method, which approximates the first-in, first-out method. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The Company routinely assesses its on-hand inventory for timely identification and measurement of obsolete, slow-moving or otherwise impaired inventory. Net inventories consisted of the following (in thousands): June 30, 2019 December 31, 2018 Parts and supplies $ 42,152 $ 39,873 Work-in-progress 14,262 11,847 Finished goods 13,106 11,530 $ 69,520 $ 63,250

FAIR VALUE (Notes)

FAIR VALUE (Notes)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 5 — FAIR VALUE MEASUREMENT Accounting Standards Codification (ASC) 820 “Fair Value Measurement” (ASC 820) defines fair value, establishes a framework for measuring fair value under U.S. GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. ASC 820 describes a fair value hierarchy based on the following three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company determines the fair value of its investment portfolio assets by obtaining non-binding market prices from its third-party portfolio managers on the last day of the quarter, whose sources may use quoted prices in active markets for identical assets (Level 1 inputs) or inputs other than quoted prices that are observable either directly or indirectly (Level 2 inputs) in determining fair value. There were no transfers between Level 1, Level 2 or Level 3 measurements for the six-month period ended June 30, 2019 . The following table represents the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018 (in thousands): Fair Value Measurements as of June 30, 2019 Using Level 1 Level 2 Level 3 Total Assets: Money market funds $ 706 $ — $ — $ 706 Minority interest investments - short-term $ — $ — $ 840 $ 840 Minority interest investments - long-term $ — $ — $ 1,782 $ 1,782 Fair Value Measurements as of December 31, 2018 Using Level 1 Level 2 Level 3 Total Assets: Money market funds $ 704 $ — $ — $ 704 Minority interest investments - long-term $ — $ — $ 2,782 $ 2,782

GOODWILL

GOODWILL	6 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill Disclosure [Text Block]	NOTE 6 — GOODWILL AND OTHER INTANGIBLE ASSETS On December 31, 2018, the Company completed the Acquisition. As a result of the Acquisition, the Company recorded approximately $32.8 million of goodwill and $30.1 million of other identifiable intangible assets. The goodwill is derived from expected synergies from combining operations of the Company and the business acquired in connection with the Acquisition. The purchase price allocation is preliminary as the Company’s determination of the fair values of the assets acquired and liabilities assumed is still in progress. A portion of the Company’s goodwill is not expected to be deductible for tax purposes. The changes in the carrying amount of goodwill during the period are as follows (in thousands): June 30, 2019 December 31, 2018 Balance at beginning of period $ 118,127 $ 85,481 Flow cytometry acquisition $ 166 $ 32,646 Balance at end of period $ 118,293 $ 118,127

INTANGIBLE ASSETS

INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	The Company’s intangible assets are reflected in the table below (in thousands, except weighted average lives): Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2018 Balance as of December 31, 2017 $ 81,385 $ 19,097 $ 5,664 $ 12,982 $ 119,128 Flow cytometry acquisition 17,084 4,722 4,991 6,703 33,500 Asset acquisition — — — 4,328 4,328 Balance as of December 31, 2018 98,469 23,819 10,655 24,013 156,956 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2017 (34,414 ) (7,037 ) (1,692 ) — (43,143 ) Amortization expense (6,087 ) (1,999 ) (579 ) — (8,665 ) Accumulated amortization balance as of December 31, 2018 (40,501 ) (9,036 ) (2,271 ) — (51,808 ) Net balance as of December 31, 2018 $ 57,968 $ 14,783 $ 8,384 $ 24,013 $ 105,148 Weighted average life (in years) 11 10 10 2019 Balance as of December 31, 2018 $ 98,469 $ 23,819 $ 10,655 $ 24,013 $ 156,956 Flow cytometry acquisition purchase price allocation adjustments (116 ) (428 ) 1,154 (4,016 ) (3,406 ) Balance as of June 30, 2019 98,353 23,391 11,809 19,997 $ 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2018 (40,501 ) (9,036 ) (2,271 ) — (51,808 ) Amortization expense (3,892 ) (1,214 ) (597 ) — (5,703 ) Accumulated amortization balance as of June 30, 2019 (44,393 ) (10,250 ) (2,868 ) — (57,511 ) Net balance as of June 30, 2019 $ 53,960 $ 13,141 $ 8,941 $ 19,997 $ 96,039 Weighted average life (in years) 11 10 10 The Company currently has three IP R&D projects. The first relates to the development of the next generation VERIGENE ® System, VERIGENE II, on which the Company began clinical trials in May 2018. The Company believes the VERIGENE II will launch commercially in 2019. The second is a defensive IP R&D project related to the Company’s next generation xMAP ® System, SENSIPLEX™, which the Company believes will launch commercially in 2020. The third relates to the development of the next generation Guava System, acquired as part of the Acquisition (Guava Next Gen System). The fair value of the Guava Next Gen System IP R&D project was determined using the income approach. The discount rate applied to the projected cash flows was 13.0%, which reflects the engineering and technical risks related to the projects. The allocation of the purchase price is preliminary and subject to change, based on the finalization of income tax matters. The Company believes the Guava Next Gen System will launch in the first quarter of 2020. The estimated costs to complete these IP R&D projects are approximately $7.9 million . The estimated aggregate amortization expense for the next five fiscal years and thereafter is as follows (in thousands): 2019 (six months) $ 5,704 2020 11,406 2021 11,048 2022 9,801 2023 9,452 Thereafter 28,631 $ 76,042

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Comprehensive Income (Loss) Note [Text Block]	NOTE 7 — OTHER COMPREHENSIVE LOSS Other comprehensive loss represents a measure of all changes in equity that result from recognized transactions and other economic events other than those resulting from investments by, and distributions to, shareholders. Other comprehensive loss for the Company includes foreign currency translation adjustments and net unrealized holding gains and losses on available-for-sale investments. The following table presents the changes in each component of accumulated other comprehensive loss, net of tax (in thousands): Accumulated Other Comprehensive Loss Items - Foreign Currency Balance as of December 31, 2018 $ (1,127 ) Other comprehensive loss (42 ) Net current-period other comprehensive loss (42 ) Balance as of June 30, 2019 $ (1,169 ) There are no material tax benefits or expenses related to the other comprehensive loss for the three and six months ended June 30, 2019 .

ACCRUED LIABILITIES (Notes)

ACCRUED LIABILITIES (Notes)	6 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 10 — ACCRUED LIABILITIES Accrued liabilities consisted of the following (in thousands): June 30, 2019 December 31, 2018 Compensation and employee benefits $ 13,104 $ 18,086 Dividends payable 2,733 2,703 Income and other taxes 691 1,014 Warranty costs 1,625 1,901 Royalties payable 1,671 1,373 Current operating lease liabilities 5,039 — Other 1,296 1,695 $ 26,159 $ 26,772 The following table summarizes the changes in the warranty accrual (in thousands): Accrued warranty costs as of December 31, 2018 $ 1,901 Warranty adjustments/settlements 1,397 Accrual for warranty costs (1,673 ) Accrued warranty costs as of June 30, 2019 $ 1,625

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 12 — INCOME TAXES At the end of each interim reporting period, an estimate is made of the effective tax rate expected to be applicable for the full year. The estimated full year’s effective tax rate is used to determine the income tax rate for each applicable interim reporting period. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period of the enactment date. The effective tax rate for the six months ended June 30, 2019 was a benefit of 79% , including amounts recorded for discrete events. This differs from the statutory rate of 21% primarily as a result of a reduction in unrecognized tax benefit liability and the effect of foreign operations. The Company’s tax expense reflects the full federal, various state, and foreign blended statutory rates. The Company currently expects a 2019 full year effective tax rate of 10% to 20% , excluding amounts recorded for discrete events. The Company will be subject to provisions regarding U.S. federal taxation of foreign intangible income and has included in its estimate of income tax the effects of this tax. The Company is utilizing its net operating losses (NOLs) and tax credits in the U.S., Canada and the Netherlands and, therefore, cash taxes to be paid are expected to be less than 10% of book tax expense. In the first quarter of 2019, U.S. tax legislation was enacted which provided guidance on the U.S. federal transition tax on earnings of foreign subsidiaries and as a result, the Company revised its Earnings and Profits (E&P) calculations for its Canadian subsidiary and discrete income tax expense of $414,000 for the U.S. transition tax has been recorded for the six month period ended June 30, 2019. The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, Australia, Canada, China, France, Germany, Hong Kong, Japan, the Netherlands, the U.K., and various U.S. states. Due to net operating losses, the U.S., Canadian and Netherlands tax returns dating back to 2015, 2007, and 2013, respectively, can still be reviewed by the taxing authorities. In the first quarter of 2019, the Company recorded a reduction in unrecognized tax benefit liability related to the U.S. transition tax and a related income tax benefit of $6.6 million as a result of a ruling for certain aspects of the E&P calculation of its Canadian subsidiary. The Company does not expect any material changes to the unrecognized tax benefit liability within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in the provision for income taxes.

EARNINGS PER SHARE

EARNINGS PER SHARE	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
EARNINGS PER SHARE	NOTE 8 — EARNINGS (LOSS) PER SHARE A reconciliation of the denominators used in computing per share net income (EPS) is as follows (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Basic: Net income (loss) $ (4,931 ) $ 5,669 $ (1,971 ) $ 19,066 Less: allocation to participating securities 35 (98 ) (2 ) (325 ) Net income (loss) attributable to common stockholders $ (4,896 ) $ 5,571 $ (1,973 ) $ 18,741 Weighted average common stock outstanding 44,157 43,734 44,054 43,599 Net income (loss) per share attributable to common stockholders $ (0.11 ) $ 0.13 $ (0.04 ) $ 0.43 Diluted: Net income (loss) $ (4,931 ) $ 5,669 $ (1,971 ) $ 19,066 Less: allocation to participating securities 34 (98 ) (3 ) (324 ) Net income (loss) attributable to common stockholders $ (4,897 ) $ 5,571 $ (1,974 ) $ 18,742 Weighted average common stock outstanding 44,157 43,734 44,054 43,599 Effect of dilutive securities: stock options and awards — 512 — 272 Weighted-average shares used in computing net income per share 44,157 44,246 44,054 43,871 Net income (loss) per share attributable to common stockholders $ (0.11 ) $ 0.13 $ (0.04 ) $ 0.43 Basic net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and common equivalent shares outstanding during the period. Restricted stock awards (RSAs) and stock options to acquire 1,860,646 and 758,250 shares for the three months ended June 30, 2019 and 2018 , and 1,267,172 and 631,044 shares for the six months ended June 30, 2019 and 2018 , respectively, were excluded from the computations of diluted earnings per share because the effect of including the RSAs and stock options would have been anti-dilutive. We apply the two-class method of computing earnings per share, which requires the calculation of separate earnings per share amounts for our non-vested, time-based restricted stock awards with non-forfeitable dividends and for our common stock. Our non-vested, time-based restricted stock awards with non-forfeitable dividends are considered securities which participate in undistributed earnings with common stock. Under the two-class computation method, net losses are not allocated to participating securities unless the holder of the security has a contractual obligation to share in the losses. Our non-vested, time-based restricted stock awards with non-forfeitable dividends do not have such an obligation so they are not allocated losses.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 9 — STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION Dividends On May 21, 2019 , the Board of Directors declared a cash dividend on the Company’s common stock of $0.06 per share. The dividend was payable to stockholders of record as of June 20, 2019 and was paid on July 11, 2019 . The Company’s current intent is to pay a continuing dividend on a quarterly basis. However, future declarations of dividends are subject to the final determination of the Company’s Board of Directors. Stock-Based Compensation The Company’s stock option activity for the six months ended June 30, 2019 is as follows: Stock Options Shares (in thousands) Weighted Average Exercise Price Outstanding at December 31, 2018 3,323 $ 19.05 Granted 977 24.43 Exercised (45 ) 17.69 Canceled or expired (333 ) 21.51 Outstanding at June 30, 2019 3,922 $ 20.18 The Company had $13.3 million of total unrecognized compensation costs related to stock options at June 30, 2019 that are expected to be recognized over a weighted-average period of 2.78 years . The Company’s restricted share activity for the six months ended June 30, 2019 is as follows: Restricted Stock Awards (RSAs) Shares (in thousands) Weighted Average Grant Price Non-vested at December 31, 2018 724 $ 20.27 Granted 402 24.19 Vested (258 ) 19.63 Cancelled or expired (31 ) 21.52 Non-vested at June 30, 2019 837 $ 22.30 Restricted Stock Units (RSUs) Shares (in thousands) Non-vested at December 31, 2018 468 Granted 128 Vested (45 ) Cancelled or expired (2 ) Non-vested at June 30, 2019 549 As of June 30, 2019 , there were $18.4 million and $3.9 million of unrecognized compensation costs related to RSAs and RSUs, respectively. These costs are expected to be recognized over a weighted average-period of 2.87 years for the RSAs and 2.31 years for the RSUs. The Company issues a small number of cash-settled RSUs pursuant to the Company’s equity incentive plan in certain foreign countries. These grants do not result in the issuance of common stock and are considered immaterial by the Company. The following are the stock-based compensation costs recognized in the Company’s Condensed Consolidated Statements of Comprehensive Income (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Cost of revenue $ 501 $ 406 $ 960 $ 816 Research and development 520 537 507 200 Selling, general and administrative 2,635 2,604 4,662 3,792 Stock-based compensation costs reflected in net income $ 3,656 $ 3,547 $ 6,129 $ 4,808

CONTINGENCIES

CONTINGENCIES	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 13 — COMMITMENTS AND CONTINGENCIES In the normal course of business, the Company is subject to claims, lawsuits and legal proceedings. When it appears probable in management’s judgment, and based upon consultation with outside counsel, that we will incur monetary damages or other costs in connection with any claims or proceedings, and such costs can be reasonably estimated, we record the estimated liability in the financial statements. If only a range of estimated losses can be estimated, we record an amount within the range that, in management’s judgment, reflects the most likely outcome; if none of the estimates within that range is a better estimate than any other amount, we record the liability at the low end of the range of estimates. Any such accrual would be charged to expense in the appropriate period. We disclose significant contingencies when the loss is not probable and/or the amount of the loss is not estimable, when we believe there is at least a reasonable possibility that a loss has been incurred. We recognize costs associated with legal proceedings in the period in which the services were provided. Leases We have leased all of our research, manufacturing and office space and have entered into various other agreements in conducting our business. Our leases have remaining lease terms of 1 year to 6 years, and some of our leases include options to extend the leases for up to 10 years, tenant improvement allowances, rent holidays and rent escalation clauses. At inception, we determine whether an agreement represents a lease and at commencement we evaluate each lease agreement to determine whether the lease is an operating or financing lease. As described below under “Note 14 - Recent Accounting Pronouncements - Recently adopted accounting guidance,” the Company adopted the new lease guidance as of January 1, 2019. Pursuant to the new lease guidance, all of the Company’s leases outstanding on January 1, 2019 continued to be classified as operating leases. With the adoption of the new lease guidance, the Company recorded an operating lease right-of-use asset and an operating lease liability on its balance sheet. Right-of-use lease assets represent the Company’s right to use the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s leases do not provide an implicit rate, we have used an estimated incremental borrowing rate of 5.75% , based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. For all lease agreements we combine lease and non-lease components. Leases with an initial term of twelve months or less are not recorded on the balance sheet. The components of the lease expense were as follows (in thousands): Six Months Ended June 30, 2019 Operating lease cost $ 4,591 Supplemental cash flow information related to leases was as follows (in thousands): Six Months Ended June 30, 2019 Lease liabilities arising from obtaining right to use assets Operating leases recorded upon lease standard adoption $ 24,922 Supplemental balance sheet information related to leases was as follows (in thousands): June 30, 2019 Operating leases: Operating lease right-of-use assets $ 22,886 Operating lease liabilities $ 24,798 Weighted Average Remaining Lease Term 4.77 years Weighted Average Discount Rate 5.75 % Maturities of lease liabilities for the next five fiscal years and thereafter are as follows (in thousands): Operating Leases 2019 (six months) $ 3,366 2020 6,400 2021 6,191 2022 4,635 2023 3,972 Thereafter 3,896 Total lease payments 28,460 Less: imputed interest (3,662 ) Lease liabilities at June 30, 2019 $ 24,798

RECENT ACCOUNTING (Notes)

RECENT ACCOUNTING (Notes)	6 Months Ended
	Jun. 30, 2019
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 14 — RECENT ACCOUNTING PRONOUNCEMENTS Recently adopted accounting guidance In May 2014, the FASB issued a new standard on revenue recognition, which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company adopted the Standard effective January 1, 2018, using the modified retrospective approach. Under this method, the Company recorded a cumulative adjustment increasing retained earnings of $10.6 million before related tax impacts or $8.1 million net of related tax impacts. See Note 11, “Revenue Recognition” for additional discussion related to the Company’s adoption of the Standard. Under the Standard, estimated royalty revenue will be recorded each quarter on an accrual basis to more closely coincide with the timing of the end user sale by the strategic partner; with reconciliation made upon submission of the royalty report by the partner indicating actual royalties owed in the following quarter. In addition, the Company began recording the portion of reagent rental revenue associated with the recovery of the cost of providing the system and other hardware in reagent rental agreements as system revenue rather than assay revenue effective January 1, 2018. This change has not and is not expected to have any impact on top line revenue and the Company does not anticipate any material effects to its revenue categorization. In February 2016, the FASB issued guidance requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases, with the exception of short-term leases. On January 1, 2019, the Company elected to adopt this new lease guidance using a simplified transition option that allows companies to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company also elected to adopt the package of practical expedients permitted in the new lease guidance. Accordingly, the Company is continuing to account for its existing operating leases as operating leases under the new lease guidance, without reassessing whether the contracts contain a lease under the new lease guidance or whether classification of the operating leases would be different under the new lease guidance. All of our leases at the adoption date were operating leases, primarily for facilities, and did not include any non-lease components.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recent accounting guidance not yet adopted In June 2016, the FASB issued guidance on financial instruments and related credit losses. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The statement of comprehensive income reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2020. Early adoption is permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements.

REVENUE RECOGNITION (Notes)

REVENUE RECOGNITION (Notes)	6 Months Ended
	Jun. 30, 2019
Revenue Recognition and Deferred Revenue [Abstract]
Revenue Recognition, Deferred Revenue [Policy Text Block]	NOTE 11 — REVENUE RECOGNITION On January 1, 2018, the Company adopted the new standard on revenue recognition, Accounting Standard Codification 606 (the Standard), using the modified retrospective transition method consistent with the guidance issued by the Financial Accounting Standards Board (FASB) in May 2014. Under this method, the Company applied the guidance retrospectively, only to those contracts which were not completed as of the date of initial application, and recognized the cumulative effect of initially applying the Standard as an adjustment to the opening balance of retained earnings as of January 1, 2018. The Standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under the Standard, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the Standard, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of the Standard, the Company assesses the goods or services promised within each contract, identifies the performance obligations and assesses whether each promised good or service is distinct. The Company allocates the total transaction price to each performance obligation in an amount based on the estimated relative standalone selling price of the promised good or service underlying each performance obligation and recognizes this as revenue when such performance obligation is satisfied. Contract assets are included within accounts receivables, net and contract liabilities are included in deferred revenue on the Company’s Balance Sheet. The following table presents the opening and closing balances of the Company’s contract assets and liabilities as of June 30 , 2019 (in thousands): Balance at December 31, 2018 Balance at June 30, 2019 Contract assets: Unbilled receivables - Royalties $ 10,805 $ 12,531 Contract liabilities - Short-term: Deferred revenue - Service $ 9,476 $ 7,937 Deferred revenue - Licenses 227 217 Deferred revenue - Instruments — 553 Deferred revenue - Other 396 267 Total contract liabilities - Short-term $ 10,099 $ 8,974 Contract liabilities - Long-term: Deferred revenue - Service $ 207 $ 2,192 Deferred revenue - Licenses 872 764 Total contract liabilities - Long-term $ 1,079 $ 2,956 During the six months ended June 30 , 2019 , the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the period (in thousands): Six Months Ended June 30, 2019 Revenue recognized in the period: Amounts included as contract liabilities at the beginning of the period $ 3,902 Performance obligations satisfied in previous periods -

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Business Description and Accounting Policies [Text Block]	NOTE 1 — BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared by Luminex Corporation (the Company or Luminex) in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring entries) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 . These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the 2018 10-K).

BUSINESS COMBINATIONS Business

BUSINESS COMBINATIONS Business Combinations - Pro Forma (Policies)	6 Months Ended
	Jun. 30, 2019
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information [Table Text Block]	Net tangible assets assumed as of December 31, 2018 $ 8,725 Intangible assets subject to amortization 30,094 Deferred tax liabilities (3,653 ) Goodwill 32,812 Total purchase price $ 67,978

INVESTMENTS (Tables)

INVESTMENTS (Tables)	6 Months Ended
	Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Other Investments Not Readily Marketable [Table Text Block]	June 30, 2019 December 31, 2018 Purchased technology rights (net of accumulated amortization of $7,957 and $7,633 in June 30, 2019 and December 31, 2018, respectively) $ 6,329 $ 6,653 Minority interest investments 1,782 2,782 Other 1,589 1,963 $ 9,700 $ 11,398
Marketable Securities [Table Text Block]	Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 706 $ — $ — $ 706 Total current securities 706 — — 706 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 706 $ — $ — $ 706
Cost-method Investments, Description [Text Block]	Non-Marketable Securities and Other-Than-Temporary Impairment During the year ended December 31, 2018, the Company made a $1.8 million investment in a private company. Based in the U.S., this minority investment is included at cost in other long-term assets of the Company’s Consolidated Balance Sheets. The Company does not have significant influence over the investee since the Company owns less than 20% of the voting equity in the investee. Further, the Company does not participate in policy-making processes or interchange managerial personnel. In August 2018, the Company exercised its purchase option on a second private company and acquired 100% of its capital stock in a non-cash transaction involving (i) a prior investment of $2.0 million being applied to the purchase option, (ii) the forgiveness and application of a $2.4 million note and related interest receivable to the purchase option and (iii) a tax impact of $0.1 million . This acquisition was accounted for as an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, a next generation technology. The Company has recorded the $4.3 million asset acquisition as a defensive, in-process research and development (IP R&D) intangible asset. There were no gains or losses recognized as part of this transaction. The Company owns a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We have been informed that this private company will be dissolving and ceasing operations in the short-term and that Luminex can expect to have the majority of its investment returned, although we cannot be certain of this. We recorded an impairment of $160,000 in Other income, net in the Consolidated Statements of Comprehensive Income during the second quarter of 2019 based upon these circumstances and communication from this private company. This minority interest is included at cost in other short-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee, as the Company owns less than 20% of the voting equity and the investee is not publicly traded. These investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the $160,000 impairment in the second quarter of 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments, As the inputs utilized for the Company’s periodic impairment assessment are not based on observable market data, the determination of fair value of its investments is classified within Level 3 of the fair value hierarchy. See Note 5 - Fair Value Measurement to our Condensed Consolidated Financial Statements for further information on the fair value hierarchy and the three classification levels. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, an investment’s fair value is not estimated as there are no identified events or changes in the circumstances. There have been no unrealized gains or losses related to these Level 3 minority interest investments.
Investments and Other Noncurrent Assets [Text Block]	NOTE 3 — INVESTMENTS AND OTHER ASSETS Marketable Securities The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. As of June 30, 2019 , the Company had no short or long-term investments, since those funds were used to pay for acquisitions. Available-for-sale securities consisted of the following as of June 30, 2019 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 706 $ — $ — $ 706 Total current securities 706 — — 706 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 706 $ — $ — $ 706 Available-for-sale securities consisted of the following as of December 31, 2018 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 704 $ — $ — $ 704 Total current securities 704 — — 704 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 704 $ — $ — $ 704 There were no proceeds from the sales of available-for-sale securities for the three and six months ended June 30, 2019 and the year ended December 31, 2018 . Realized gains and losses on sales of investments are determined using the specific identification method and are included in other income (expense) in the Condensed Consolidated Statements of Comprehensive Income. There were no available-for-sale debt securities as of June 30, 2019 or December 31, 2018 . All of the Company’s available-for-sale securities with gross unrealized losses as of June 30, 2019 had been in a loss position for less than 12 months. Non-Marketable Securities and Other-Than-Temporary Impairment During the year ended December 31, 2018, the Company made a $1.8 million investment in a private company. Based in the U.S., this minority investment is included at cost in other long-term assets of the Company’s Consolidated Balance Sheets. The Company does not have significant influence over the investee since the Company owns less than 20% of the voting equity in the investee. Further, the Company does not participate in policy-making processes or interchange managerial personnel. In August 2018, the Company exercised its purchase option on a second private company and acquired 100% of its capital stock in a non-cash transaction involving (i) a prior investment of $2.0 million being applied to the purchase option, (ii) the forgiveness and application of a $2.4 million note and related interest receivable to the purchase option and (iii) a tax impact of $0.1 million . This acquisition was accounted for as an asset acquisition rather than a business combination, as substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, a next generation technology. The Company has recorded the $4.3 million asset acquisition as a defensive, in-process research and development (IP R&D) intangible asset. There were no gains or losses recognized as part of this transaction. The Company owns a minority interest in another private company based in the U.S. through its initial investment of $1.0 million in the third quarter of 2012. We have been informed that this private company will be dissolving and ceasing operations in the short-term and that Luminex can expect to have the majority of its investment returned, although we cannot be certain of this. We recorded an impairment of $160,000 in Other income, net in the Consolidated Statements of Comprehensive Income during the second quarter of 2019 based upon these circumstances and communication from this private company. This minority interest is included at cost in other short-term assets on the Company’s Consolidated Balance Sheets as the Company does not have significant influence over the investee, as the Company owns less than 20% of the voting equity and the investee is not publicly traded. These investments do not have readily determinable fair values. Therefore, the Company has elected the measurement alternative for its minority interests and the investments are recorded at cost, less any impairment, including changes resulting from observable price changes. The Company regularly evaluates the carrying value of its investment for impairment and whether any events or circumstances are identified that would significantly harm the fair value of the investment. The primary indicators the Company utilizes to identify these events and circumstances are the investee’s ability to remain in business, such as the investee’s liquidity and rate of cash use, and the investee’s ability to secure additional funding and the value of that additional funding. In the event a decline in fair value is less than the investment’s carrying value, the Company will record an impairment charge in Other income, net in the Consolidated Statements of Comprehensive Income. Other than the $160,000 impairment in the second quarter of 2019 discussed above, the Company has not recorded any impairment charges related to these non-marketable investments, As the inputs utilized for the Company’s periodic impairment assessment are not based on observable market data, the determination of fair value of its investments is classified within Level 3 of the fair value hierarchy. See Note 5 - Fair Value Measurement to our Condensed Consolidated Financial Statements for further information on the fair value hierarchy and the three classification levels. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, an investment’s fair value is not estimated as there are no identified events or changes in the circumstances. There have been no unrealized gains or losses related to these Level 3 minority interest investments. Other long-term assets consisted of the following (in thousands): June 30, 2019 December 31, 2018 Purchased technology rights (net of accumulated amortization of $7,957 and $7,633 in June 30, 2019 and December 31, 2018, respectively) $ 6,329 $ 6,653 Minority interest investments 1,782 2,782 Other 1,589 1,963 $ 9,700 $ 11,398 For the six months ended June 30, 2019 and 2018 , the Company recognized amortization expenses related to the amortization of purchased technology rights of approximately $324,000 and $293,000 , respectively. Future amortization expenses are estimated to be $324,000 in the remaining six months of 2019 , $547,000 in 2020 , $515,000 in 2021 , $497,000 in 2022 , $481,000 in 2023 and $3,965,000 thereafter.
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	Marketable Securities The Company determines the appropriate classification of any investments in debt and equity securities at the time of purchase and re-evaluates such determinations at each balance sheet date. As of June 30, 2019 , the Company had no short or long-term investments, since those funds were used to pay for acquisitions. Available-for-sale securities consisted of the following as of June 30, 2019 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 706 $ — $ — $ 706 Total current securities 706 — — 706 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 706 $ — $ — $ 706 Available-for-sale securities consisted of the following as of December 31, 2018 (in thousands): Amortized Cost Gains in Accumulated Other Comprehensive Income Losses in Accumulated Other Comprehensive Income Estimated Fair Value Current: Money market funds $ 704 $ — $ — $ 704 Total current securities 704 — — 704 Noncurrent: Total noncurrent securities — — — — Total available-for-sale securities $ 704 $ — $ — $ 704 There were no proceeds from the sales of available-for-sale securities for the three and six months ended June 30, 2019 and the year ended December 31, 2018 . Realized gains and losses on sales of investments are determined using the specific identification method and are included in other income (expense) in the Condensed Consolidated Statements of Comprehensive Income. There were no available-for-sale debt securities as of June 30, 2019 or December 31, 2018 . All of the Company’s available-for-sale securities with gross unrealized losses as of June 30, 2019 had been in a loss position for less than 12 months.

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Components of Inventories	June 30, 2019 December 31, 2018 Parts and supplies $ 42,152 $ 39,873 Work-in-progress 14,262 11,847 Finished goods 13,106 11,530 $ 69,520 $ 63,250

FAIR VALUE (Tables)

FAIR VALUE (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]	Fair Value Measurements as of June 30, 2019 Using Level 1 Level 2 Level 3 Total Assets: Money market funds $ 706 $ — $ — $ 706 Minority interest investments - short-term $ — $ — $ 840 $ 840 Minority interest investments - long-term $ — $ — $ 1,782 $ 1,782

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill [Table Text Block]	Finite-lived Indefinite-lived Technology, trade secrets and know-how Customer lists and contracts Other identifiable intangible assets IP R&D Total 2018 Balance as of December 31, 2017 $ 81,385 $ 19,097 $ 5,664 $ 12,982 $ 119,128 Flow cytometry acquisition 17,084 4,722 4,991 6,703 33,500 Asset acquisition — — — 4,328 4,328 Balance as of December 31, 2018 98,469 23,819 10,655 24,013 156,956 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2017 (34,414 ) (7,037 ) (1,692 ) — (43,143 ) Amortization expense (6,087 ) (1,999 ) (579 ) — (8,665 ) Accumulated amortization balance as of December 31, 2018 (40,501 ) (9,036 ) (2,271 ) — (51,808 ) Net balance as of December 31, 2018 $ 57,968 $ 14,783 $ 8,384 $ 24,013 $ 105,148 Weighted average life (in years) 11 10 10 2019 Balance as of December 31, 2018 $ 98,469 $ 23,819 $ 10,655 $ 24,013 $ 156,956 Flow cytometry acquisition purchase price allocation adjustments (116 ) (428 ) 1,154 (4,016 ) (3,406 ) Balance as of June 30, 2019 98,353 23,391 11,809 19,997 $ 153,550 Less: accumulated amortization: Accumulated amortization balance as of December 31, 2018 (40,501 ) (9,036 ) (2,271 ) — (51,808 ) Amortization expense (3,892 ) (1,214 ) (597 ) — (5,703 ) Accumulated amortization balance as of June 30, 2019 (44,393 ) (10,250 ) (2,868 ) — (57,511 ) Net balance as of June 30, 2019 $ 53,960 $ 13,141 $ 8,941 $ 19,997 $ 96,039 Weighted average life (in years) 11 10 10
Estimated Future Amortization Expense Related to Intangible Assets	2019 (six months) $ 5,704 2020 11,406 2021 11,048 2022 9,801 2023 9,452 Thereafter 28,631 $ 76,042

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	6 Months Ended
	Jun. 30, 2019
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	June 30, 2019 December 31, 2018 Compensation and employee benefits $ 13,104 $ 18,086 Dividends payable 2,733 2,703 Income and other taxes 691 1,014 Warranty costs 1,625 1,901 Royalties payable 1,671 1,373 Current operating lease liabilities 5,039 — Other 1,296 1,695 $ 26,159 $ 26,772
Schedule of Product Warranty Liability [Table Text Block]	Accrued warranty costs as of December 31, 2018 $ 1,901 Warranty adjustments/settlements 1,397 Accrual for warranty costs (1,673 ) Accrued warranty costs as of June 30, 2019 $ 1,625

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Basic and Diluted Earnings Per Share	Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 Basic: Net income (loss) $ (4,931 ) $ 5,669 $ (1,971 ) $ 19,066 Less: allocation to participating securities 35 (98 ) (2 ) (325 ) Net income (loss) attributable to common stockholders $ (4,896 ) $ 5,571 $ (1,973 ) $ 18,741 Weighted average common stock outstanding 44,157 43,734 44,054 43,599 Net income (loss) per share attributable to common stockholders $ (0.11 ) $ 0.13 $ (0.04 ) $ 0.43 Diluted: Net income (loss) $ (4,931 ) $ 5,669 $ (1,971 ) $ 19,066 Less: allocation to participating securities 34 (98 ) (3 ) (324 ) Net income (loss) attributable to common stockholders $ (4,897 ) $ 5,571 $ (1,974 ) $ 18,742 Weighted average common stock outstanding 44,157 43,734 44,054 43,599 Effect of dilutive securities: stock options and awards — 512 — 272 Weighted-average shares used in computing net income per share 44,157 44,246 44,054 43,871 Net income (loss) per share attributable to common stockholders $ (0.11 ) $ 0.13 $ (0.04 ) $ 0.43

Business Combinations - Additio

Business Combinations - Additional Information (Detail) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2018USD ($)
Business Combinations [Abstract]
Acquisition date		Dec. 31, 2018
Total consideration transferred	$ 75,000
Cash paid to acquire the business	68,000
Transactions recognized separately from preliminary purchase price allocation	5,100	$ 5,100
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Assets	8,725	8,725
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	30,094	30,094
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	(3,653)	(3,653)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	32,812	32,812
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	$ 67,978	$ 67,978

INVESTMENTS Details (Details)

INVESTMENTS Details (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Cost-method Investments, Realized Losses	$ 160,000
Document Period End Date	Jun. 30, 2019
Cost Method Investments, Original Cost	$ 1,782,000	$ 2,782,000
Prepaid Expense and Other Assets, Noncurrent	1,589,000	1,963,000
Other Assets, Noncurrent	9,700,000	11,398,000
Licensing Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	$ 6,329,000	$ 6,653,000

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory, Raw Materials and Purchased Parts, Net of Reserves	$ 42,152	$ 39,873
Inventory, Work in Process, Net of Reserves	14,262	11,847
Inventory, Finished Goods, Net of Reserves	13,106	11,530
Inventory, Net	$ 69,520	$ 63,250

FAIR VALUE (Details)

FAIR VALUE (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 706	$ 704
Cost Method Investments, Fair Value Disclosure	1,782	2,782
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	706	704
Cost Method Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Cost Method Investments, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Cost Method Investments, Fair Value Disclosure	$ 1,782	$ 2,782

GOODWILL (Details)

GOODWILL (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 118,293		$ 118,127	$ 85,481
Goodwill, Acquired During Period	$ 166	$ 32,646

INTANGIBLE ASSETS (Detail)

INTANGIBLE ASSETS (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	$ 5,704				$ 5,704
Finite-Lived Intangible Assets, Accumulated Amortization	(57,511)	$ (51,808)			(57,511)		$ (51,808)	$ (43,143)
Indefinite-lived Intangible Assets (Excluding Goodwill)	19,997	24,013			19,997		24,013	12,982
Finite-Lived Intangible Assets, Amortization Expense, after Year Five	28,631				28,631
Finite-Lived Intangible Assets, Amortization Expense, Year Three	11,048				11,048
Finite-Lived Intangible Assets, Amortization Expense, Year Two	11,406				11,406
Finite-Lived Intangible Assets, Amortization Expense, Year Four	9,801				9,801
Finite-Lived Intangible Assets, Amortization Expense, Year Five	9,452				9,452
Intangible Assets, Net (Excluding Goodwill)	96,039	105,148			96,039		105,148
Intangible Assets, Gross (Excluding Goodwill)	153,550	156,956			153,550		156,956	119,128
Indefinite-lived Intangible Assets, Purchase Accounting Adjustments					(4,016)
Indefinite-lived Intangible Assets Acquired		6,703	$ 4,328
Amortization of Intangible Assets, IA	(2,852)			$ (2,166)	(5,704)	$ (4,332)	(8,665)
Technology-Based Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(44,393)	(40,501)			(44,393)		(40,501)	(34,414)
Finite-Lived Intangible Assets, Gross	98,353	98,469			98,353		98,469	81,385
Finite-Lived Intangible Assets, Net	53,960	57,968			$ 53,960		$ 57,968
Finite-Lived Intangible Asset, Useful Life					11 years		11 years
Finite-Lived Intangible Assets, Purchase Accounting Adjustments					$ (116)
Finite-lived Intangible Assets Acquired		17,084
Amortization of Intangible Assets, IA					(3,892)		$ (6,087)
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(10,250)	(9,036)			(10,250)		(9,036)	(7,037)
Finite-Lived Intangible Assets, Gross	23,391	23,819			23,391		23,819	19,097
Finite-Lived Intangible Assets, Net	13,141	14,783			$ 13,141		$ 14,783
Finite-Lived Intangible Asset, Useful Life					10 years		10 years
Finite-Lived Intangible Assets, Purchase Accounting Adjustments					$ (428)
Finite-lived Intangible Assets Acquired		4,722
Amortization of Intangible Assets, IA					(1,214)		$ (1,999)
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization	(2,868)	(2,271)			(2,868)		(2,271)	(1,692)
Finite-Lived Intangible Assets, Gross	11,809	10,655			11,809		10,655	$ 5,664
Finite-Lived Intangible Assets, Net	$ 8,941	8,384			$ 8,941		$ 8,384
Finite-Lived Intangible Asset, Useful Life					10 years		10 years
Finite-Lived Intangible Assets, Purchase Accounting Adjustments					$ 1,154
Finite-lived Intangible Assets Acquired		$ 4,991
Amortization of Intangible Assets, IA					$ (597)		$ (579)

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME Details (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (1,169)		$ (1,169)		$ (1,127)
Other Comprehensive Income (Loss), Net of Tax	91	$ (711)	(42)	$ (319)
Foreign Currency Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (1,169)		$ (1,169)		$ (1,127)

ACCRUED LIABILITIES (Details)

ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Employee-related Liabilities, Current	$ 13,104	$ 18,086
Taxes Payable, Current	691	1,014
Product Warranty Accrual, Current	1,625	1,901
Accrued Royalties, Current	1,671	1,373
Operating Lease, Liability, Current	5,039	0
Standard and Extended Product Warranty Accrual, Decrease for Payments	(1,673)
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued	1,397
Dividends Payable, Current	2,733	2,703
Other Accrued Liabilities, Current	1,296	1,695
Accrued Liabilities, Current	$ 26,159	$ 26,772

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Effective tax rate			79.00%
U.S. federal statutory tax rate			21.00%
Provision for income taxes	$ (983)	$ 2,197	$ (7,467)	$ 4,515
Income (Loss) Attributable to Parent, before Tax	$ (5,914)	$ 7,866	$ (9,438)	$ 23,581

EARNINGS PER SHARE Details (Det

EARNINGS PER SHARE Details (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Participating Securities, Distributed and Undistributed Earnings (Loss), Basic	$ 35		$ (98)	$ (2)	$ (325)
Net Income (Loss) Available to Common Stockholders, Basic	$ (4,896)		$ 5,571	$ (1,973)	$ 18,741
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,860,646		758,250	1,267,172	631,044
Net Income (Loss) Available to Common Stockholders, Diluted	$ (4,897)		$ 5,571	$ (1,974)	$ 18,742
Weighted Average Number of Shares Outstanding, Basic	44,157,000		43,734,000	44,054,000	43,599,000
Earnings Per Share, Basic	$ (0.11)		$ 0.13	$ (0.04)	$ 0.43
Net Income (Loss) Attributable to Parent	$ (4,931)	$ 2,960	$ 5,669	$ (1,971)	$ 19,066
Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted	$ 34		$ (98)	$ (3)	$ (324)
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0		512,000	0	272,000
Weighted Average Number of Shares Outstanding, Diluted	44,157,000		44,246,000	44,054,000	43,871,000
Earnings Per Share, Diluted	$ (0.11)		$ 0.13	$ (0.04)	$ 0.43

STOCKHOLDERS' EQUITY Details (D

STOCKHOLDERS' EQUITY Details (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividends Payable, Date Declared	May 21, 2019
Dividends Payable, Date of Record	Jun. 20, 2019
Dividends Payable, Date to be Paid	Jul. 11, 2019
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 13.3	$ 13.3
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	549	549	468
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		128
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		(45)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period		(2)
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 3 months 21 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 3.9	$ 3.9
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	837	837	724
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 22.30	$ 22.30	$ 20.27
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period		402
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 24.19
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		(258)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value		$ 19.63
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period		(31)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value		$ 21.52
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 10 months 13 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 18.4	$ 18.4
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 9 months 10 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,922	3,922	3,323
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 20.18	$ 20.18	$ 19.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		977
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 24.43
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		(45)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price		$ 17.69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period		(333)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price		$ 21.51

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)Rate
Commitments and Contingencies Disclosure [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	4 years 9 months 7 days
Lease, Cost	$ 4,591
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year	3,366
Operating Leases, Future Minimum Payments, Due in Two Years	6,400
Operating Leases, Future Minimum Payments, Due in Three Years	6,191
Operating Leases, Future Minimum Payments, Due in Four Years	4,635
Operating Leases, Future Minimum Payments, Due in Five Years	3,972
Operating Leases, Future Minimum Payments, Due Thereafter	3,896
Operating Leases, Future Minimum Payments Due	$ 28,460
Operating Lease, Weighted Average Discount Rate, Percent | Rate	5.75%